Screening of NXP900 and dasatinib across 121 cancer cell lines identifies differences in their antiproliferative activity profiles
- King, B.
- Hughes, R.E.
- Navarro-Marchal, S.
- Brunton, V.G.
- Poradosu, E.
- Carragher, N.O.
- Unciti-Broceta, A.
ISSN: 1879-0852, 0959-8049
Year of publication: 2022
Volume: 174
Pages: S113
Type: Article